Valuation : Delcath Systems, Inc.

Market Cap 572M 492M 463M 423M 791M 53.99B 793M 5.47B 2.12B 27.7B 2.15B 2.1B 89.24B P/E 2026 *
-110x
P/E 2027 * -206x
Enterprise Value 572M 492M 463M 423M 791M 53.99B 793M 5.47B 2.12B 27.7B 2.15B 2.1B 89.24B EV / Sales 2026 *
5.38x
EV / Sales 2027 * 4.33x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 week+0.86%
Current month+0.12%
1 month+25.42%
3 months+52.73%
6 months+78.55%
Current year+63.17%
1 week 16.1
Extreme 16.1
16.78
1 month 14
Extreme 14
17.42
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
525,609,756.1
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.86%+48.47%+239.09% 572M
-1.14%+0.79%-0.70%-31.15% 18.5B
-0.68%+0.17%-1.18%+0.82% 17.23B
+1.26%+4.88%-52.23%-46.72% 6.73B
-1.35%-3.00% - - 4.34B
+3.62%+11.46%+36.99%+81.43% 2.15B
-0.86%-2.21%-10.99%-4.80% 1.9B
+0.72%-1.99%-49.76%-57.61% 1.13B
-0.13%-3.66%+48.50%+145.34% 941M
+3.27%+0.72% - - 305M
Average +0.47%+0.86%+2.39%+40.80% 5.38B
Weighted average by Cap. -0.42%+0.98%-6.29%-10.22%

Financials

2026 *2027 *
Net sales 106M 91.39M 85.99M 78.55M 147M 10.03B 147M 1.02B 394M 5.15B 399M 390M 16.57B 132M 114M 107M 97.61M 183M 12.46B 183M 1.26B 490M 6.39B 496M 485M 20.6B
Net income -5.72M -4.92M -4.63M -4.23M -7.92M -540M -7.94M -54.73M -21.24M -277M -21.48M -21.02M -893M -3.39M -2.92M -2.74M -2.51M -4.69M -320M -4.7M -32.41M -12.58M -164M -12.72M -12.44M -529M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-09-04 US$16.48 0.00% 180,916
26-09-03 US$16.48 -0.60% 268,647
26-09-02 US$16.58 +1.10% 448,647
26-09-01 US$16.40 -0.36% 360,378
26-08-31 US$16.46 +0.73% 402,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.48USD
Average target price
24.00USD
Spread / Average Target
+45.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock